TB Research

3-Aryl-substituted imidazo[1,2-a]pyridines as antituberculosis agents

Karale UB, Shinde AU, Babar DA, Sangu KG, Vagolu SK, Eruva VK, Jadav SS, Misra S, et al. (10 authors)

Archiv der Pharmazie · 2021-06

Abstract

Novel inhibitors are needed to tackle tuberculosis. Herein, we report the 3-aryl-substituted imidazo[1,2-a]pyridines as potent antituberculosis agents. A small library of 3-aryl-substituted imidazo[1,2-a]pyridines was synthesized using direct arylation, followed by nitro reduction and finally Pd-catalyzed C-N coupling reactions. The compounds thus obtained were evaluated against Mycobacterium tuberculosis H37Rv. Compound 26 was identified as an antituberculosis lead with a minimum inhibitory concentration of 2.3 μg/ml against M. tuberculosis H37Rv. This compound showed a selectivity index of 35. The docking of 26 in the active site of the M. tuberculosis cytochrome bc1 complex cytochrome b subunit (Mtb QcrB) revealed key π-π interactions of compound 26 with the Tyr389 and Trp312 residues of Mtb QcrB.

MeSH terms

  • Mycobacterium tuberculosis
  • Pyridines
  • Antitubercular Agents
  • Microbial Sensitivity Tests
  • Structure-Activity Relationship
  • Molecular Docking Simulation